MYMD Key Statistics, Chart & Performance
The current stock price of MYMD is 1.82 USD. In the past month the price decreased by -2.15%. In the past year, price decreased by -94.48%.
MYMD Technical Analysis
MYMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYMD. MYMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MYMD Financial Highlights
Over the last trailing twelve months MYMD reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 52.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.43% | ||
| ROE | -43.95% | ||
| Debt/Equity | 0 |
MYMD Forecast & Estimates
MYMD Ownership
MYMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.35 | 984.41B | ||
| JNJ | JOHNSON & JOHNSON | 21.02 | 525.73B | ||
| MRK | MERCK & CO. INC. | 12.42 | 271.66B | ||
| PFE | PFIZER INC | 7.98 | 145.10B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.27 | 110.38B | ||
| ZTS | ZOETIS INC | 19.44 | 54.31B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.51 | 22.56B | ||
| VTRS | VIATRIS INC | 5.43 | 14.58B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.17 | 12.00B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.30B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.52B |
Related stock screener links
About MYMD
Company Profile
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Company Info
MYMD PHARMACEUTICALS INC
855 N. Wolfe Street, Suite 601
Baltimore MARYLAND 08086 US
CEO: Christopher C. Schreiber
Employees: 9
Phone: 18568488698
MYMD PHARMACEUTICALS INC / MYMD FAQ
What does MYMD PHARMACEUTICALS INC do?
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
What is the current price of MYMD stock?
The current stock price of MYMD is 1.82 USD.
Does MYMD PHARMACEUTICALS INC pay dividends?
MYMD does not pay a dividend.
How is the ChartMill rating for MYMD PHARMACEUTICALS INC?
MYMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for MYMD PHARMACEUTICALS INC?
MYMD PHARMACEUTICALS INC (MYMD) has a market capitalization of 4.20M USD. This makes MYMD a Nano Cap stock.